DelistingApr 29, 2026, 08:42 AM
SGMO to be Delisted from Nasdaq; Trading Suspended May 5; Moves to OTCQB
AI Summary
Sangamo Therapeutics, Inc. (SGMO) received a delisting notice from Nasdaq due to its failure to meet the minimum bid price requirement. Trading of its common stock on The Nasdaq Capital Market will be suspended on May 5, 2026. The company plans to appeal the delisting decision, but this will not prevent the trading suspension. Concurrently, SGMO has secured approval for its common stock to be quoted on the OTCQB Venture Market, with trading expected to begin on May 5, 2026, under its current symbol "SGMO."
Key Highlights
- SGMO received Nasdaq delisting notice on April 28, 2026, for minimum bid price non-compliance.
- Nasdaq trading suspension for SGMO common stock effective May 5, 2026.
- Company plans to appeal Nasdaq delisting decision.
- Appeal will not stay the trading suspension on Nasdaq.
- SGMO approved for OTCQB Venture Market listing.
- Trading on OTCQB expected to commence May 5, 2026, under symbol "SGMO".
Price Impact
More from SGMO